X

Trial Profile

Effectiveness of Intravenous Immunoglobulins (IVIG) in Toxic Shock Syndromes in Children: a Multicentre European Randomized Controlled Trial

Status: Withdrawn prior to enrolment

Phase of Trial: Phase IV

Latest Information Update: 05 Nov 2021

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Immune globulin (Primary) ; Albumin human
Indications Septic shock; Staphylococcal infections; Streptococcal infections
Focus Therapeutic Use
Acronyms IGHN2

Most Recent Events

28 Apr 2021 Status changed from not yet recruiting to withdrawn prior to enrolment as no EC approval obtained.
18 Dec 2019 Planned End Date changed from 1 Apr 2022 to 1 Sep 2024.
18 Dec 2019 Planned primary completion date changed from 1 Apr 2022 to 1 Sep 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com